CU24401B1 - Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7) - Google Patents
Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7)Info
- Publication number
- CU24401B1 CU24401B1 CU2016000160A CU20160160A CU24401B1 CU 24401 B1 CU24401 B1 CU 24401B1 CU 2016000160 A CU2016000160 A CU 2016000160A CU 20160160 A CU20160160 A CU 20160160A CU 24401 B1 CU24401 B1 CU 24401B1
- Authority
- CU
- Cuba
- Prior art keywords
- sup
- sub
- hepatitis
- tlr7
- toll
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101100099924 Drosophila melanogaster Toll-7 gene Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 208000009621 actinic keratosis Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000004193 respiratory failure Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987321P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/028264 WO2015168269A1 (en) | 2014-05-01 | 2015-04-29 | Compounds and compositions as toll-like receptor 7 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160160A7 CU20160160A7 (es) | 2017-04-05 |
| CU24401B1 true CU24401B1 (es) | 2019-05-03 |
Family
ID=53284501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000160A CU24401B1 (es) | 2014-05-01 | 2015-04-29 | Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7) |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9902730B2 (enExample) |
| EP (1) | EP3137470B1 (enExample) |
| JP (1) | JP6484253B2 (enExample) |
| KR (1) | KR102139847B1 (enExample) |
| CN (1) | CN106232603B (enExample) |
| AP (1) | AP2016009485A0 (enExample) |
| AR (1) | AR100244A1 (enExample) |
| AU (1) | AU2015253215B2 (enExample) |
| BR (1) | BR112016025423A2 (enExample) |
| CA (1) | CA2946408C (enExample) |
| CL (1) | CL2016002751A1 (enExample) |
| CR (1) | CR20160512A (enExample) |
| CU (1) | CU24401B1 (enExample) |
| DO (1) | DOP2016000295A (enExample) |
| EA (1) | EA030603B1 (enExample) |
| ES (1) | ES2877050T3 (enExample) |
| GT (1) | GT201600233A (enExample) |
| IL (1) | IL248347B (enExample) |
| MX (1) | MX362341B (enExample) |
| NI (1) | NI201600164A (enExample) |
| NZ (1) | NZ724792A (enExample) |
| PE (1) | PE20170325A1 (enExample) |
| PH (1) | PH12016501966B1 (enExample) |
| PL (1) | PL3137470T3 (enExample) |
| PT (1) | PT3137470T (enExample) |
| SG (1) | SG11201608161VA (enExample) |
| SV (1) | SV2016005311A (enExample) |
| TW (1) | TWI666212B (enExample) |
| UY (1) | UY36103A (enExample) |
| WO (1) | WO2015168269A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106459058B (zh) | 2014-05-01 | 2019-07-05 | 诺华股份有限公司 | 作为toll-样受体7激动剂的化合物和组合物 |
| CN110759916B (zh) | 2014-08-15 | 2021-02-19 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| KR102394917B1 (ko) | 2015-03-04 | 2022-05-09 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| CR20180109A (es) * | 2015-07-20 | 2018-05-03 | Genzyme Corp | Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r) |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043377A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| PT3507276T (pt) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | Compostos moduladores do recetor de tipo toll |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| CN106727768A (zh) * | 2017-02-06 | 2017-05-31 | 灞卞嘲 | 一种治疗子宫内膜炎的药物组合物 |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| US12128047B2 (en) * | 2018-05-25 | 2024-10-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| CN113271938A (zh) * | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| ES2960987T3 (es) | 2019-04-12 | 2024-03-07 | Riboscience Llc | Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EP3980423A1 (en) * | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| MY208114A (en) | 2019-09-30 | 2025-04-16 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| EP4097102A1 (en) * | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| CN115151548A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| US20230140430A1 (en) | 2020-01-27 | 2023-05-04 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132602A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| JP2023512230A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしてのＣ３置換１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| US12485123B2 (en) | 2020-01-27 | 2025-12-02 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists |
| KR20220132592A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| CN115210235A (zh) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| KR20220132601A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0530537B1 (en) | 1991-08-12 | 1997-01-08 | Takeda Chemical Industries, Ltd. | Condensed pyrimidine derivatives, their production and use as antitumor agents |
| JPH10501532A (ja) | 1994-06-09 | 1998-02-10 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗物質 |
| WO2000068213A1 (en) | 1999-05-05 | 2000-11-16 | Aventis Pharma Limited | Substituted bicyclic compounds |
| CN1918158B (zh) * | 2004-02-14 | 2011-03-02 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| EP1728792A4 (en) * | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
| WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| MXPA06013996A (es) | 2004-06-02 | 2007-02-08 | Takeda Pharmaceutical | Compuesto heterociclico fusionado. |
| UA91508C2 (ru) * | 2004-06-02 | 2010-08-10 | Такеда Фармасьютикал Компани Лимитед | Конденсированное гетероциклическое соединение |
| RU2383545C2 (ru) | 2005-03-15 | 2010-03-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| WO2007034917A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| ES2541434T3 (es) * | 2007-06-29 | 2015-07-20 | Gilead Sciences, Inc. | Derivados de purina y su uso como moduladores del receptor de tipo Toll 7 |
| MX2010008719A (es) | 2008-02-06 | 2010-09-24 | Novartis Ag | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2011140338A1 (en) | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| WO2011162515A2 (en) | 2010-06-23 | 2011-12-29 | Hanmi Holdings Co. , Ltd. | Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity |
| WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| EP2570125A1 (en) | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ep1 receptor ligands |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| KR102280595B1 (ko) * | 2012-10-10 | 2021-07-22 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체 |
| CN106459058B (zh) | 2014-05-01 | 2019-07-05 | 诺华股份有限公司 | 作为toll-样受体7激动剂的化合物和组合物 |
| TW201632515A (zh) | 2015-01-23 | 2016-09-16 | 協友股份有限公司 | 經取代之吡唑吡唑衍生物及其作爲除草劑的用途 |
-
2015
- 2015-04-29 KR KR1020167030101A patent/KR102139847B1/ko not_active Expired - Fee Related
- 2015-04-29 UY UY0001036103A patent/UY36103A/es not_active Application Discontinuation
- 2015-04-29 NZ NZ724792A patent/NZ724792A/en not_active IP Right Cessation
- 2015-04-29 CA CA2946408A patent/CA2946408C/en not_active Expired - Fee Related
- 2015-04-29 CN CN201580021618.9A patent/CN106232603B/zh active Active
- 2015-04-29 AU AU2015253215A patent/AU2015253215B2/en not_active Ceased
- 2015-04-29 PE PE2016002146A patent/PE20170325A1/es unknown
- 2015-04-29 EP EP15727098.4A patent/EP3137470B1/en active Active
- 2015-04-29 US US15/307,525 patent/US9902730B2/en active Active
- 2015-04-29 BR BR112016025423A patent/BR112016025423A2/pt not_active IP Right Cessation
- 2015-04-29 CU CU2016000160A patent/CU24401B1/es unknown
- 2015-04-29 ES ES15727098T patent/ES2877050T3/es active Active
- 2015-04-29 CR CR20160512A patent/CR20160512A/es unknown
- 2015-04-29 MX MX2016014305A patent/MX362341B/es active IP Right Grant
- 2015-04-29 SG SG11201608161VA patent/SG11201608161VA/en unknown
- 2015-04-29 AP AP2016009485A patent/AP2016009485A0/en unknown
- 2015-04-29 PT PT157270984T patent/PT3137470T/pt unknown
- 2015-04-29 PL PL15727098T patent/PL3137470T3/pl unknown
- 2015-04-29 WO PCT/US2015/028264 patent/WO2015168269A1/en not_active Ceased
- 2015-04-29 JP JP2016565398A patent/JP6484253B2/ja active Active
- 2015-04-29 EA EA201692177A patent/EA030603B1/ru not_active IP Right Cessation
- 2015-04-30 AR ARP150101310A patent/AR100244A1/es unknown
- 2015-04-30 TW TW104113993A patent/TWI666212B/zh not_active IP Right Cessation
-
2016
- 2016-10-04 PH PH12016501966A patent/PH12016501966B1/en unknown
- 2016-10-13 IL IL248347A patent/IL248347B/en active IP Right Grant
- 2016-10-28 NI NI201600164A patent/NI201600164A/es unknown
- 2016-10-28 CL CL2016002751A patent/CL2016002751A1/es unknown
- 2016-10-31 GT GT201600233A patent/GT201600233A/es unknown
- 2016-11-01 DO DO2016000295A patent/DOP2016000295A/es unknown
- 2016-11-01 SV SV2016005311A patent/SV2016005311A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24401B1 (es) | Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7) | |
| NZ629728A (en) | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| MX380777B (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| PH12017500854B1 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| BR112015020998A2 (pt) | compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| GEP20186921B (en) | Pyrazolopyridines and pyrazolopyrimidines | |
| PH12016501633A1 (en) | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| CL2012001073A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias. | |
| PH12017501339A1 (en) | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | |
| MX2017000980A (es) | Composiciones de tratamiento. | |
| PH12014502413A1 (en) | Cyclic bridgehead ether dgat1 inhibitors | |
| MX2017000976A (es) | Composiciones de tratamiento. | |
| MA40076A (fr) | Inhibiteurs de syk | |
| PH12020550201A1 (en) | N-acyl-n-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| MX2017014478A (es) | Derivado de heteroarilo o su sal farmaceuticamente aceptable, su metodo de preparacion y composicion farmaceutica para la prevencion o tratamiento de enfermedades asociadas con pi3 cinasas que contiene el mismo como ingrediente activo. | |
| PE20200387A1 (es) | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer | |
| CL2017000703A1 (es) | Anticuerpos anti-il-25 y usos de los mismos | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| MX2017005283A (es) | Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik). | |
| AR090596A1 (es) | Formulaciones farmaceuticas que comprenden antagonistas de ccr3 | |
| DOP2019000047A (es) | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres | |
| UY36377A (es) | Compuestos tiazoles sustituidos como moduladores del receptor nuclear ror t y composiciones farmacéuticas que los contienen | |
| BR112015008992A2 (pt) | compostos de acilaminocicloalquila adequados para tratamento de distúrbios que respondem à modulação de receptor d3 de dopamina | |
| MY178136A (en) | Novel imidazopyridazine compounds and their use |